Anavex Life Sciences Corp (AVXL)

[Joseph_K]

MABs exacerbate brain volume loss.

People in two large lecanemab trials on the highest drug dose—which is the one the U.S. Food and Drug Administration (FDA) approved—recorded, on average, a 28% greater brain volume loss relative to placebo after about 18 months. This translated to a loss of an extra 5.2 milliliters (mL) in brain matter.
https://www.science.org/content/article/promising-alzheimer-s-therapy-and-related-drugs-shrink-brains#:~:text=People%20in%20two%20large%20lecanemab,(mL)%20in%20brain%20matter.

Hoskuld, you understated your case!

AD patients lose significant brain volume annually (unabated when using mab therapies.)

I should state that I've also come across a hypothesis that the brain volume loss from MABs comes directly from the loss of plaque itself (I suppose in contrast to loss of neurons), and so is not a bad thing. It may have been a Saabagh piece where I read that. (I'm not saying I subscribe to that hypothesis.)